No­var­tis ex­pands Scem­blix la­bel to first-line CML pa­tients

No­var­tis’ chron­ic myeloid leukemia drug Scem­blix will now be avail­able to new­ly di­ag­nosed pa­tients, the FDA an­nounced on Tues­day.

Scem­blix was first ap­proved in 2021 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA